Giant cell tumour of bone in the denosumab era

被引:112
作者
van der Heijden, Lizz [1 ]
Dijkstra, P. D. Sander [1 ]
Blay, Jean-Yves [2 ]
Gelderblom, Hans [3 ]
机构
[1] Leiden Univ, Med Ctr, Dept Orthoped Surg, Leiden, Netherlands
[2] Ctr Leon Berard, Dept Med Oncol, Lyon, France
[3] Leiden Univ, Med Ctr, Dept Med Oncol, Postzone K1-62,POB 9600, NL-2300 RC Leiden, Netherlands
关键词
Denosumab; RANK ligand; Giant cell tumour of bone; ZOLEDRONIC ACID; LOCAL RECURRENCE; MUSCULOSKELETAL TUMORS; PATHOLOGICAL FRACTURE; MOLECULAR ANALYSIS; RADIATION-THERAPY; STROMAL CELLS; RISK-FACTORS; OPEN-LABEL; RADIOTHERAPY;
D O I
10.1016/j.ejca.2017.02.021
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Giant cell tumour of bone (GCTB) is an intermediate locally aggressive primary bone tumour, occurring mostly at the meta-epiphysis of long bones. Overexpression of receptor activator of nuclear factor kappa-B ligand (RANKL) by mononuclear neoplastic stromal cells promotes recruitment of numerous reactive multinucleated osteoclast-like giant cells, causing lacunar bone resorption. Preferential treatment is curettage with local adjuvants such as phenol, alcohol or liquid nitrogen. The remaining cavity may be filled with bone graft or polymethylmethacrylate (PMMA) bone cement; benefits of the latter are a lower risk of recurrence, possibility of direct weight bearing and early radiographic detection of recurrences. Reported recurrence rates are comparable for the different local adjuvants (27-31%). Factors increasing the local recurrence risk include soft tissue extension and anatomically difficult localisations such as the sacrum. When joint salvage is impossible, en-bloc resection and endoprosthetic joint replacement may be performed. Local tumour control on the one hand and maintenance of a functional native joint and quality of life on the other hand are the main pillars of surgical treatment for this disease. Current knowledge and development in the fields of imaging, functional biology and systemic therapy are forcing us into a paradigm shift from a purely surgical approach towards a multidisciplinary approach. Systemic therapy with denosumab (RANKL inhibitor) or zoledronic acid (bisphosphonates) blocks, respectively inhibits, bone resorption by osteoclast-like giant cells. After use of zoledronic acid, stabilisation of local and metastatic disease has been reported, although the level of evidence is low. Denosumab is more extensively studied in two prospective trials, and appears effective for the optimisation of surgical treatment. Denosumab should be considered in the standard multidisciplinary treatment of advanced GCTB (e.g. cortical destruction, soft tissue extension, joint involvement or sacral localisation) to facilitate surgery at a later stage, and thereby aiming at immediate local control. Even though several questions concerning optimal treatment dose, duration and interval and drug safety remain unanswered, denosumab is among the most effective drug therapies in oncology. (C) 2017 Elsevier Ltd. All rights reserved.
引用
收藏
页码:75 / 83
页数:9
相关论文
共 85 条
[31]   Current status and unanswered questions on the use of Denosumab in giant cell tumor of bone [J].
Gaston, Czar Louie ;
Grimer, Robert J. ;
Parry, Michael ;
Stacchiotti, Silvia ;
Tos, Angelo Paolo Dei ;
Gelderblom, Hans ;
Ferrari, Stefano ;
Baldi, Giacomo G. ;
Jones, Robin L. ;
Chawla, Sant ;
Casali, Paolo ;
LeCesne, Axel ;
Blay, Jean-Yves ;
Dijkstra, Sander P. D. ;
Thomas, David M. ;
Rutkowski, Piotr .
CLINICAL SARCOMA RESEARCH, 2016, 6
[32]   UK guidelines for the management of bone sarcomas [J].
Gerrand, Craig ;
Athanasou, Nick ;
Brennan, Bernadette ;
Grimer, Robert ;
Judson, Ian ;
Morland, Bruce ;
Peake, David ;
Seddon, Beatrice ;
Whelan, Jeremy .
CLINICAL SARCOMA RESEARCH, 2016, 6
[33]   Denosumab treated giant cell tumour of bone: a morphological, immunohistochemical and molecular analysis of a series [J].
Girolami, Ilaria ;
Mancini, Irene ;
Simoni, Antonella ;
Baldi, Giacomo Giulio ;
Simi, Lisa ;
Campanacci, Domenico ;
Beltrami, Giovanni ;
Scoccianti, Guido ;
D'Arienzo, Antonio ;
Capanna, Rodolfo ;
Franchi, Alessandro .
JOURNAL OF CLINICAL PATHOLOGY, 2016, 69 (03) :240-247
[34]   Giant cell tumors of the spine: has denosumab changed the treatment paradigm? [J].
Goldschlager, Tony ;
Dea, Nicolas ;
Boyd, Michael ;
Reynolds, Jeremy ;
Patel, Shreyaskumar ;
Rhines, Laurence D. ;
Mendel, Ehud ;
Pacheco, Marina ;
Ramos, Edwin ;
Mattei, Tobias A. ;
Fisher, Charles G. .
JOURNAL OF NEUROSURGERY-SPINE, 2015, 22 (05) :526-533
[35]   Cytogenetic Analysis of 101 Giant Cell Tumors of Bone: Nonrandom Patterns of Telomeric Associations and Other Structural Aberrations [J].
Gorunova, Ludmila ;
von Steyern, Fredrik Vult ;
Storlazzi, Clelia Tiziana ;
Bjerkehagen, Bodil ;
Folleras, Gunnar ;
Heim, Sverre ;
Mandahl, Nils ;
Mertens, Fredrik .
GENES CHROMOSOMES & CANCER, 2009, 48 (07) :583-602
[36]   Critical Hypercalcemia Following Discontinuation of Denosumab Therapy for Metastatic Giant Cell Tumor of Bone [J].
Gossai, Nathan ;
Hilgers, Megan V. ;
Polgreen, Lynda E. ;
Greengard, Emily G. .
PEDIATRIC BLOOD & CANCER, 2015, 62 (06) :1078-1080
[37]   Adjuvant treatment with zoledronic acid after extensive curettage for giant cell tumours of bone [J].
Gouin, Francois ;
Rochwerger, Alexandre R. ;
Di Marco, Antonio ;
Rosset, Philippe ;
Bonnevialle, Paul ;
Fiorenza, Fabrice ;
Anract, Philippe .
EUROPEAN JOURNAL OF CANCER, 2014, 50 (14) :2425-2431
[38]   Outcome of Conservative Surgery for Giant Cell Tumor of the Sacrum [J].
Guo, Wei ;
Ji, Tao ;
Tang, Xiaodong ;
Yang, Yi .
SPINE, 2009, 34 (10) :1025-1031
[39]   Osteogenic capacity of nanocrystalline bone cement in a weight-bearing defect at the ovine tibial metaphysis [J].
Harms, Christoph ;
Helms, Kai ;
Taschner, Tibor ;
Stratos, Ioannis ;
Ignatius, Anita ;
Gerber, Thomas ;
Lenz, Solvig ;
Rammelt, Stefan ;
Vollmar, Brigitte ;
Mittlmeier, Thomas .
INTERNATIONAL JOURNAL OF NANOMEDICINE, 2012, 7 :2883-2889
[40]   Smooth muscle actin expression in primary bone tumours [J].
Hemingway, F. ;
Kashima, T. G. ;
Mahendra, G. ;
Dhongre, A. ;
Hogendoorn, P. C. W. ;
Mertens, F. ;
Athanasou, N. A. .
VIRCHOWS ARCHIV, 2012, 460 (05) :525-534